


Accepted Manuscript

Cholesterol efflux capacity of large, small and total HDL particles is unaltered by atorvastatin in patients with type 2 diabetes

Liliana Muñoz-Hernandez, Raul J. Ortiz-Bautista, Griselda Brito-Córdova, Francisco Lozano-Arvizu, Sharim Saucedo, Oscar Pérez-Méndez, Alejandro Zentella-Dehesa, Carolane Dauteuille, Marie Lhomme, Philippe Lesnik, M. John Chapman, Anatol Kontush, Carlos A. Aguilar Salinas



PII: S0021-9150(18)31333-9

DOI: [10.1016/j.atherosclerosis.2018.08.027](https://doi.org/10.1016/j.atherosclerosis.2018.08.027)

Reference: ATH 15673

To appear in: *Atherosclerosis*

Received Date: 30 April 2018

Revised Date: 24 July 2018

Accepted Date: 23 August 2018

Please cite this article as: Muñoz-Hernandez L, Ortiz-Bautista RJ, Brito-Córdova G, Lozano-Arvizu F, Saucedo S, Pérez-Méndez O, Zentella-Dehesa A, Dauteuille C, Lhomme M, Lesnik P, Chapman MJ, Kontush A, Aguilar Salinas CA, Cholesterol efflux capacity of large, small and total HDL particles is unaltered by atorvastatin in patients with type 2 diabetes, *Atherosclerosis* (2018), doi: 10.1016/j.atherosclerosis.2018.08.027.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1

2 **Cholesterol efflux capacity of large, small and total HDL particles is unaltered by atorvastatin in**
3 **patients with type 2 diabetes**

4 Liliana Muñoz-Hernandez ^{a,b}, Raul J Ortiz-Bautista ^a, Griselda Brito-Córdova ^c, Francisco
5 Lozano-Arvizu ^a, Sharim Saucedo ^c, Oscar Pérez-Méndez ^d, Alejandro Zentella-Dehesa ^e,
6 Carolane Dauteuille ^f, Marie Lhomme ^f, Philippe Lesnik ^f, M John Chapman ^f, Anatol
7 Kontush, ^f Carlos A. Aguilar Salinas ^{a,c,g},

8 ^a Unidad de Investigación de Enfermedades Metabólicas, Instituto Nacional de Ciencias
9 Médicas y Nutrición Salvador Zubirán. Avenue Vasco de Quiroga 15, Tlalpán CP 14080,
10 Mexico City, Mexico.

11 ^bConsejo Nacional de Ciencia y Tecnología (CONACyT). Avenue Insurgentes Sur 1582,
12 Crédito Constructor ; Benito Juárez CP 03940, Mexico City, Mexico

13 ^c Departamento de Endocrinología y Metabolismo. Instituto Nacional de Ciencias Médicas
14 y Nutrición Salvador, Avenue Vasco de Quiroga 15, Tlalpán CP 14080, Mexico City,
15 Mexico.

16 ^dDepartamento de Biología Molecular. Instituto Nacional de Cardiología Ignacio Chávez,
17 Avenue Juan Badiano1, Tlalpán CP 14080, Mexico City, Mexico.

18 ^eDepartamento de Bioquímica, Instituto Nacioncal de Ciencias Médicas y Nutrición
19 Salvador Zubirán, Avenue Vasco de Quiroga 15, Tlalpán CP 14080, Mexico City, Mexico.

20 ^fNational Institute for Health and Medical Research (INSERM), UMR 1166 ICAN, UPMC
21 Paris 6, Hospital La Pitié - Salpêtrière, Paris F-75013, France

22 ^g Tecnológico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Calle del puente
23 222, Ejidos de Huipulco, Tlalpán 14380, Mexico City, México

Download English Version:

<https://daneshyari.com/en/article/8956964>

Download Persian Version:

<https://daneshyari.com/article/8956964>

[Daneshyari.com](https://daneshyari.com)